A MODELED HEALTH ECONOMIC ANALYSIS OF THE ACCUCATH® INTRAVASCULAR CATHETER SYSTEM WITH RETRACTABLE COILED TIP GUIDEWIRE COMPARED WITH CONVENTIONAL PERIPHERAL INTRAVASCULAR CATHETERS

Author(s)

Kara R1, Hollmann S2, Ferko N2, Delatore P3
1Bard Access Systems, Salt Lake City, UT, USA, 2Cornerstone Research Group Inc., Burlington, ON, Canada, 3CR Bard Inc., Murray Hill, NJ, USA

OBJECTIVES:  AccuCath® Catheters are an innovative guidewire and catheter combination designed to increase first-attempt success. A health economic model was developed from a U.S. hospital perspective to compare the costs associated with increased adoption of AccuCath® Catheter versus conventional peripheral intravascular catheters (PIVC). METHODS:  The model was built to compare current care, assuming a mix of conventional PIVCs (98%) and AccuCath® Catheter (2%), to a future scenario with increased utilization of AccuCath® Catheter, assuming 90% conventional PIVCs and 10% AccuCath® Catheter. The analysis was conducted for a hypothetical annual cohort of 30,000 patients with an average hospital length of stay (LOS) of 4.5 days. The analysis was stratified by two populations: 1) all patients requiring PIVC placement (i.e., approximately 70% of patients admitted annually), and 2) a subgroup of patients requiring a PIVC placement who have difficult venous access (i.e., approximately 36% of patients requiring PIVC placement). Model parameters included the number of devices and nursing time required per successful insertion, dwell time, complication rates, medical device unit costs, and material costs associated management of complications. Model inputs were derived from published literature where possible. RESULTS: For a center with 30,000 patients admitted annually, the potential one-year cost savings in the future scenario with increased use of AccuCath® Catheter may be up to $244,308 for all patients requiring PIVC placement (n=21,000; $11.63 per patient) and up to $92,238 when considering only patients with difficult venous access (n=7,560; $12.20 per patient). Overall, patients treated with AccuCath® Catheter may receive less insertions over the course of their LOS when compared with conventional PIVCs. The results were robust to a number of sensitivity analyses. CONCLUSIONS:  These analyses suggest that from a U.S. hospital perspective, the use of AccuCath® Catheter may be cost-savings when compared with conventional PIVC.

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PMD114

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis, Cost/Cost of Illness/Resource Use Studies

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×